Merck & Co (MSD) has gained European Commission approval for Enflonsia (clesrovimab), a long-acting monoclonal antibody designed to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. The authorization covers all 27 EU member states plus Iceland, Liechtenstein, and Norway. Enflonsia protects for around five months with a single, non-weight-based dose. The approval rests on results from the Phase IIb/III CLEVER and Phase III SMART trials. CLEVER reported a 60.4% reduction in medically attended RSV infections and an 84.2% cut in hospitalizations versus placebo, with a safety record equivalent to placebo. In SMART, Enflonsia delivered efficacy on par with palivizumab in high-risk infants. Actual access will rely on national reimbursement decisions, which often take months.
The clearance strengthens Merck’s position in respiratory biologics and intensifies competition in Europe’s increasingly crowded RSV prevention field. The product’s single-dose regimen stands in contrast to palivizumab’s monthly schedule, a difference likely to resonate with cost-sensitive health systems, if the price aligns with budget expectations. A simplified, non-weight-based formulation might streamline manufacturing and distribution, a quiet efficiency that could sway adoption in countries seeking to trim clinic visits and staffing burden.
Viewed commercially, Enflonsia’s five-month protection window positions it as a practical choice for public health agencies and hospital networks trying to steady RSV surges. Reimbursement outcomes will decide how much ground MSD can take from entrenched incumbents such as palivizumab. The trials point to equivalent safety and a clear decrease in severe illness, but market traction now turns on pricing discipline and procurement timing. Nobody really knows yet whether European payers will treat this as a routine seasonal intervention or a premium biologic. For a deeper payer-side breakdown on RSV prevention economics, see RxPBM.ai. And honestly, if Merck keeps the price reasonable, this one could move fast across borders.
